Bigger than Viagra?

It sounds too good to be true: a drug to help you stop smoking, stay happy and lose weight. Roger Henderson on the accidental discovery of bupropion

Tuesday July 13, 1999

Guardian

Modern medicine still relies on chance and serendipity far more than it cares to admit. Viagra, the prescription drug phenomenon of the past two years, was originally developed as a treatment for heart disease and it was only when users reported their impotence was a thing of the past that the manufacturers realised they had created a golden goose.

If reports from America are to be believed, a new drug that has properties also discovered by accident may take the United Kingdom by storm next year, and could be set to rival the success of Viagra. If approved, it may also go some way in helping health professionals to achieve their goal of reducing the number of premature deaths in this country from heart disease, as set out in the recent department of health white paper on the health of the nation.

Originally developed as an antidepressant, the drug - bupropion hydrochloride - was licensed in the US three years ago under the name Wellbutrin. Its main marketing point was that it did not greatly interfere with sexual function, something most antidepressants are notorious for affecting.

During trials of the drug, and quite by chance, it was realized that people taking Wellbutrin were finding it far easier to stop smoking than those who were not using it. Early reports suggested that they were not craving for cigarettes as they normally did, and had fewer withdrawal symptoms on stopping their habit.

Once the the company involved, Glaxo Wellcome, had picked up on this aspect of the drug, it began further trials specifically looking at the effectiveness of the drug as an anti-smoking aid. The results of this comparative clinical study were published in the New England Journal of Medicine in March this year, and make for impressive reading.

Just under 900 smokers were involved, all of whom smoked at least 15 cigarettes a day. They were split into four groups - those taking a dummy pill or placebo, those taking bupropion, those using a nicotine patch plus a bupropion tablet, and those using a nicotine patch alone.

http://www.guardian.co.uk/print/0,,3882769-103409,00.html
After 12 months, 15% of those on the dummy pill were still not smoking. This was only marginally worse than the 16% using only nicotine patches, but nearly 31% of smokers taking bupropion had stopped. The surprising statistic, however, was in the group using both patches and bupropion - a success rate of 35%, more than double the usual rate seen in smokers trying to give up.

Just as important, side effects appeared to be minor, with few people having to stop the drug because of them. A dry mouth and insomnia were reported by users, but little else. People with a history of seizures or eating disorders should not take bupropion, but otherwise most smokers will be valid candidates for such treatment, which is the first such non-nicotine prescription available.

This combination of effective results and low side effects led to the drug being licensed in the US as an aid to stopping smoking, under the name Zyban. This has now been prescribed to some 3m Americans, over 1m of whom have stopped smoking.

Some of these ex-smokers who had kicked the habit by taking Zyban appeared on the BBC Watchdog Healthcheck programme in March this year. One of them, Keith Webber, was quoted as saying: "I was thoroughly addicted to cigarettes, which seemed to be a part of me. Zyban does make it easier, does calm that irritability, it keeps you on a far more even keel in dealing with the world." Another recovered nicotine addict, Paula Covey, said: "As sure as I'm sitting here I will never have another cigarette - it's just a better life now."

Attempts are now being made to secure a licence across the EU, with the Dutch authorities taking the lead through the regulatory hoops. The drug could be available in this country early next year.

Rob Cohen, therapeutic and science communications manager of Glaxo Wellcome, says: "With success rates double that of nicotine replacement therapy, Zyban, upon approval from the appropriate regulatory authorities, will provide an effective weapon for many people in their battle against nicotine addiction.

"A combination of Zyban and the nicotine replacement patch has shown a small benefit over Zyban alone, but it should be remembered that it is the addiction to nicotine that drives us to smoke. If you can overcome this addiction without feeding it through another route then the longer-term chances of keeping cigarette-free may be increased."

The prospect of a new popular prescription drug arriving on the market will inevitably lead to much debate over funding, and the government will be keen to avoid another debacle like that over prescription of Viagra.

Costs are in the region of £2 per day, but as Clive Bates, director of Action on Smoking and Health (Ash) points out: "The big question here is whether the government will allow doctors to prescribe Zyban on the NHS at the normal prescription charge. If not, the market
could be severely limited. If they do allow it, then the demand could be enormous - of over 13m smokers in the UK, 70% would like to quit.

"I believe such treatments are extremely cost-effective because it is much cheaper to help people to quit smoking rather than pour money into the treatment of cancer or heart disease later in life."

Nicotine addiction is a medically recognised condition; more than 1bn people smoke worldwide, and 3m died from smoking-related conditions last year. The figure is expected to rise to more than 10m a year by 2025. Global sales of products to help smokers quit will exceed £500m this year, and a non-nicotine medicine may be welcomed with open arms by smokers who have repeatedly failed to give up using standard nicotine replacement treatments. And while at first glance such a treatment might appear to have a lower success rate than, say, Viagra, the large number of smokers means that there are still far more potential patients - of both sexes - who may benefit.

And there is a promising postscript to this story. At the same time as the trials of Zyban, an American psychiatrist - Dr Kishore Gadde from the Duke University in North Carolina - found that obese depressed women who were given the drug in its capacity as an antidepressant began to lose weight quicker than those not taking it, by a factor of about three.

Early trials showed this to be a consistent weight loss and the women reported they felt satisfied with smaller portions of food, so ate less. Although it remains unclear exactly why this should be the case, it is probably linked with the neurotransmitters that are responsible for the craving and reward cycle linked to eating.

"This is not a flash in the pan," says Dr Gadde. "These patients have continued with their weight loss over a year and there do not appear to be withdrawal symptoms when they stop taking the drug." Bigger trials will take place later this year, and this weight loss aspect of bupropion remains at an early stage of development, but there is already excitement in the pharmaceutical industry about it. A drug that works on depression and helps you stop smoking and may help you lose weight into the bargain? It sounds like a marketing dream.

But as the drug regulatory authorities continue their deliberations, it is probably only a matter of time before pleas for the next "wonder drug" are heard by British doctors. One thing can be sure though - decisions over who will get it and who will pay for it will be a headache for doctors, patients, and politicians alike.

Guardian Unlimited © Guardian Newspapers Limited 2006
Dr. Gadde,

AP Radio is running something on the weight study. However, we missed the deadline to speak with them yesterday. Cooney Waters will gather all resulting stories (BBC, OnHealth, Medcast, AP) and I will send them to your office.

Also, we continue to contact reporters and will let you know as opportunities arise.

I’ll be around until approx. 5:00 pm. Here’s my cell phone # again, just in case you need me: 917-846-3859!

Thanks!!
Great seeing you

Jocelyn

---

JOCelyn SERIO
SEnIOR ACOuNT AEXECUTIvE

COONEY/WATERS GROUP INC.
79 FIFTH AVENUE | NEW YORK, NY 10003
212 886-2200 | FAX 212 886-2288
DIRECT LINE 212 886-2231 | jservo@cwg.com

GDR177-0309
To: Kishore Gadde, MD

Company: Duke

Fax No.: 919-681-7421

From: Jocelyn Serr0

Message: FYI

Number of Pages including cover page: 6

Reference: 1350

If you do not receive all pages, please call 212-886-2200
is a wonder drug

Hypoglycopen doubled people's chances of stopping smoking. After a year, 36% per cent of those on the drug and the patch had stopped; and 30% per cent of those on the drug alone, 18% per cent of those using the patch alone and 10% per cent of those taking the change pill had stopped.

In 1967, hypoglycopen — now also called Zyban — was given a licence for use in America as an aid to giving up smoking. The drug quickly followed. Applications have been made for a European licence, and Zolaed, the best country; it is expected to grant a licence within months.

At this point, an American psychiatrist enters the picture. Dr. Kedem Gada, director of the multi-centre clinical trials in psychiatry, Tufts University, Durham, North Carolina, was treating a group of obese women who had put some of them on Wellbutrin, to help them with their depression. These women lost more weight than those not taking the drug. Dr. Gada set up a double-blind trial — in which neither the women nor Dr. Gada knew who was taking what. 28 women took the drug and 33 did not.

"They were all on 2,200 calories a day and their average weight was 210 lbs (15 stone 10 lbs). After eight weeks, women taking the drug had lost an average of 16 lbs compared with 8 lbs for the women taking the placebo," he said. "This is not a fluke in the pan. They have continued with their weight loss over a year. There do not appear to be-withdrawal symptoms when they stop taking the drug.

"What the women tell me is that they achieve feelings of satisfaction with smaller amounts of food. They can eat one small piece of pie and stop. If they find it hard to lose, they will eat another small piece, but no more."

One side-effect of the drug is a dry mouth. The drug is not designed for people who smoke drugs.

Dr. Gada is planning a much bigger trial this year and will review early findings in a conference in London. In the meantime, Gland Wernig continues to be cautious about hypoglycopen's latest reported benefits.

No one is quite clear how the drug works with the patient and the dieter, except that hypoglycopen acts on dopamine, a neurotransmitter — a message-changer in the brain that is involved in the reward pathways. A licence for hypoglycopen as an aid to losing weight is some way off. There is no licence application for hypoglycopen as an anti-depressant (Wellbutrin) in Western Europe, but no one is going to stop smoking Zyban. It could be licensed in Britain early next year in America, Zyban costs about £5 a day. Whether it will be available on the NHS will be up to the MIB as well as on private prescription is another story.
WEIGHT LOSS: The Latest From the Lab

Try to keep track of the latest diet and weight loss news can seem as exhausting as an ads class. So here’s a rundown of five studies that report on some winning ideas and one big loser. All were presented at the recent annual conference of the North American Association for the Study of Obesity.

Mix it up: Even a smart diet has its limits. That’s the opinion of researchers who tracked 142 dieters for a year. After 24 weeks subjects had shed roughly 30 pounds, but then weight loss tapered off. Scientists aren’t sure what caused the slump, but say you might beat it by switching diets after six months.

Move more: It’s a scary thought. A 30-minute workout may not be enough. A Brown University study suggests people must burn up to 2,800 calories a week to avoid gaining weight. That’s equal to walking an hour a day—double the government’s recommendation. The researchers urge people not to be discouraged, just to build on their good habits.

Eat your oats: In one study, people who ate three hours of oatmeal every day for six months gained 50 percent less weight compared to those who ate a placebo. A Harvard study found that chitosan, a candidate for a weight-loss supplement, helped people feel fuller longer.

Appetite suppressants: Maybe a pill can help. One that promises to block the absorption of fat in the gut. At Duke University researchers put overweight people on a diet and gave half a placebo pill and half the weight-loss pill. After six weeks those who took the pill lost a third of their body weight, whereas the control group lost only 5 percent.

Chitosan: A bust: a Swiss study suggests people who take chitosan pills to reduce fat from being absorbed. In other studies, 40 percent of the fat from being absorbed. The people who took the supplement did nothing. "I don’t know what Chitosan does," says lead researcher Hans Lengfeld. "But it’s no fat blocker."
Publication Date: Thursday, May 20, 1999

Popular Glaxo drug effective as weight loss therapy

With just more than a handful of anti-obesity drugs currently on the U.S. pharmaceutical market, Glaxo Wellcome Plc could soon add to that group a drug it already markets for treating two other conditions.

In a study of 50 obese women between 24 and 51 years old, researchers found that 67 percent lost more than 5 percent of their body weight after treatment with Glaxo's bupropion and a 1,600-calorie diet; 15 percent of those taking placebo with the diet had the same outcome.

Additionally, researchers found that women treated with bupropion lost an average of 13.7 pounds of their original weight as compared with 3.4 pounds for those taking placebo.

"The drug group lost four times more weight than the placebo group," said Dr. Kishore Gadde, who presented the study data at the 152nd annual meeting of the American Psychiatric Association. "The results were much more exciting than we expected initially."

Glaxo Wellcome markets bupropion under the name Zyban for assisting in smoking cessation and as Wellbutrin for the treatment of depression.

"It's not indicated for weight loss," Gadde said. "Until we have results replicated in a large, placebo-controlled study, I'm not recommending it."

Gadde did say, however, that he thinks bupropion might be as effective as the other drugs on the market indicated for weight loss.
to a Harvard University study published in the October 6 issue of the Journal of the American Medical Association.

The study found that men and women who ate six servings of fruits and vegetables had a 31 percent lower risk of stroke compared to those who ate fewer than three servings a day. Each additional serving eaten per day lowered the risk of stroke by 6 percent, but eating more than six servings didn't have an impact.

The reduction in risk may be the result of chemicals found in certain fruits and vegetables that prevent blood from clotting in the brain.

The best foods are in the cabbage family: broccoli, cauliflower, and bok choy. Broccoli had the greatest impact in lowering risk by 32 percent while vegetables in general only reduced the risk by 4 percent.

Also, leafy green vegetables and citrus juices were found to be particularly beneficial. In fact, having a daily glass of orange juice was linked to a 25 percent drop in the risk of stroke compared to 11 percent for other fruits.

Linda Van Horn, Ph.D., Registered Dietician and Professor of Preventive Medicine at Northwestern University says that, "Many people don't realize how easy - and fast - getting those [six] servings can be. It can be as easy as drinking a glass of orange juice in the morning, snacking on an apple in the afternoon and including a vegetable at dinner."

And if you absolutely don't want to eat your brussel sprouts, one to two glasses of alcohol a day can also reduce your risk of stroke, according to Dr. J.P. Mohr of the Columbia Presbyterian Center.

---

**Aired September 20, 1999**

**Heartburn Treatment**

For people who suffer from heartburn, a new, quick procedure provides relief so you can still eat your favorite foods.

Heartburn, or acid indigestion, is caused by Gastro-Esophageal Reflux Disease (GERD). GERD occurs when stomach acid flows back up into the esophagus caused by weak muscles where the stomach and esophagus meet.

Currently, diet and antacids are used to control mild heartburn but medications, which are expensive, may be necessary in more severe cases. Another option has been surgery which requires general anesthesia and a one to three day hospital stay. After small openings are made in the abdomen, part of the stomach is wrapped around the lower end of the esophagus.

The new treatment involves using surgical stitches during endoscopy, which is used to evaluate reflux symptoms. The stitches are supposed to tighten the area between the stomach and the esophagus to prevent heartburn. No incisions are made and the patient doesn't need anesthesia. The procedure lasts about 30 to 60 minutes.

The procedure is appropriate for people who suffer heartburn several times a week. It is currently being studied at six centers nationwide, none of them are in the tri-state area. For more information, contact: Mayo Clinic Cancer Center, 200 First Street SW, Rochester, MN 55905, (507) 284-2511.

---

**Aired August 12, 1999**

**Anti-Depressant May Help Weight Loss**

If you're trying to lose weight, a drug used to battle depression may also help battle the bulge.

Kishore Vadde, M.D., a psychiatrist at Duke University Medical Center, noticed that obese patients taking the anti-depressant Buproprion SR lost weight more successfully. He then studied 30 women who were overweight but not depressed.
and found similar results.

"The people who received bupropion SR did four times better than those who received placebo," said Dr. Gaddis.

After eight weeks, women taking the drug and eating a 1600-calorie diet lost four times more weight than women on a placebo. Women who completed the study and took the drug lost about 6 percent of their body weight compared to about 1.5 percent for women on a placebo.

The drug is marketed under the names Wellbutrin SR and Zyban. The only side effect so far seems to be dry mouth. It does not affect sexual function like other anti-depressant medications. The drug's long-term effectiveness on weight loss has not yet been tested.

It could take two years before the drug is cleared for use as a diet aid. Right now, some doctors prescribe it to help smokers kick the habit.

For more information, contact Rebecca Levine, Duke University Medical Center, Box 3354, Durham, NC 27710. (919) 684-4148.

---

Aired August 9, 1999

Exercise to Strengthen Immune System

Exercise builds muscle, fights obesity, and strengthens your immune system.

One of the ways exercise stimulates your immune system is to increase the number of infection fighting cells called natural killer cells.

But there can be too much of a good thing. Exercise physiologist Robyn Stuhr says exercising everyday or twice a day can lead to over training. She says over-training can be characterized by fatigue and exercise performance suffers.

The symptoms of over-training can be subtle. Stuhr says to give yourself recovery time, such as one to two days between each day of intense exercise.

---

Raising "Good" Cholesterol with Medication

People with cholesterol problems are often treated by their doctors to lower their "bad" cholesterol. But if your "good" cholesterol is not high enough, there's a new treatment to remedy that situation that could help prevent heart problems.

According to Dr. Henry Ginsberg, of Columbia Presbyterian Medical Center, normally about 70 percent of our cholesterol is LDL, or bad cholesterol, and about 30 percent is HDL. The HDL, or good cholesterol carries cholesterol away from the blood vessels to the liver where it can leave the body. Good cholesterol should be higher than 35 for men and higher than 40 for women.

An article in the August 5 issue of the New England Journal of Medicine confirmed that it is important to increase levels of HDL or good cholesterol if it's low. According to Dr. Hanna Bloomfield Rubins, of the Veterans Affairs Medical Center in Minneapolis, Minnesota, about 20 to 50 percent of people with heart disease have low levels of HDL cholesterol and normal levels of LDL cholesterol.

Researchers found that the inexpensive drug lopid was effective in reducing deaths from heart problems. Of the approximately 2,500 men studied, those who took the drug daily for an average of 5 years were 22 percent less likely to die from heart disease or have a nonfatal heart attack and 29 percent less likely to have a stroke. In addition to raising the HDL levels, it also helped reduce levels of the total cholesterol and other blood fats called triglycerides.
Bupropion SR, now used to treat depression and help patients quit smoking, shows promise as a potential weight loss tool.

Preliminary findings from researchers at Duke University Medical Center have shown that women who took the drug and followed a 1,600-calorie diet lost four times more weight than women who followed the diet and took a placebo. "Since the withdrawal of fenfluramine and dexfenfluramine, there has been a great need for effective medications," noted Richard Gaddis, MD, lead investigator of the study, which was presented last month during the American Psychiatric Association meeting in Washington, DC.

Gaddis's study included 31 women who did not have depression and weighed an average of 222 pounds. After 8 weeks, 18 women who took bupropion SR lost 6.2% of their body weight, while 13 women who received placebo lost 1.6% of their body weight. The data analysis is not complete, but Gaddis said it appeared that women who initially responded to the drug continued to lose weight as the study passed the 6-month mark.

JAMA, June 23/30, 1999-Vol 281, No. 24 2277

Contact Information:

Contact: Robert Rutledge, M.D. F.A.C.S.
Address: 4301 S. Franklin Blvd., P. O. Box 15608 Durham NC 27714

Toll Free Voice Mail: 1-877-584-600 ext. 202
Office Telephone #: (919) 478-4403 or (919) 479-4402
Fax #: (919) 479-4400
Hospital Paging #: (919) 479-4900
E-Mail: Dr. Rutledge@clsc.net

Warning: Gastric Bypass Surgery is a MAJOR surgical procedure.
It can be associated with significant risks and complications, up to and including death.

Disclaimer Notice:
Information on this web site is provided for informational purposes only. It is imperative that you consult your own physician regarding the applicability of any opinions or recommendations with respect to your symptoms or medical condition.
Contact with this web site or Dr. Rutledge over the web site does not constitute a doctor patient relationship and for good quality medical care you must seek advice and consultation from your own local physician.
This site is intended as a resource for references on the treatment of obesity for health care professionals and educated consumers. The authors and editors have used sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. Medical knowledge changes rapidly, in view of the possibility of human error or changes in medical science, neither the authors nor the editors nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions in the results obtained from the use of such information.
Readers are strongly encouraged to discuss and confirm the information contained herein with your own physician.

Copyright © 1998 The Center for Laparoscopic Obesity Surgery

http://olos.net/bupropion.htm
LOSE WEIGHT & STOP SMOKING

By LEE BOWMAN

WASHINGTON — A drug already approved to combat depression and help people stop smoking has shown promise as a weight-loss tool in a small, preliminary study, researchers say.

Speaking during a meeting of the American Psychiatric Association here earlier this week, Dr. Kishore Gadde of Duke University said a small group of women taking bupropion hydrochloride lost four times more weight over an eight-week period than a group of women taking inactive pills. All the women were also on a relatively modest 1,600-calorie-a-day diet.

Gadde said tests with the drug, which is sold as Zyban as a stop-smoking aid and as Wellbutrin for depression, are continuing, and that the women who responded during the first eight weeks appear to be losing additional weight as they continue taking the drug more than six months out, although the researchers haven't completed analyzing their data.

"While we have to approach the results cautiously because the long-term results are not completed, we are very excited about the potential this drug has for treating obesity," Gadde said.

The psychiatrist first noticed that the drug seemed to have an effect on weight among a group of women he was treating for mild depression at a Duke diet and fitness center.

Studies done before and after the drug was approved by the Food and Drug Administration as an anti-smoking aid in 1997 also noted that people taking the drug gained less weight as they quit smoking than ex-smokers taking a placebo pill. Tests showed that up to twice as many people on the drug quit smoking as those taking a placebo.
Gadde then approached the drug's manufacturer, Glaxo-Wellcome, with a proposal to test the drug's weight-loss properties on a group of non-depressed women weighing an average of 222 pounds.

Continued...

©1999 Scripps Howard News Service

For more articles about Health...
DATE: 6/9/99
TO: Kishore Gadde, MD
RE: 919-681-7421
PAGES: 2
CODE: 1372

NOTE: Don't know if you saw this one or not...

Jocelyn
Anti-Depressant Diet

BACKGROUND: Ninety-seven million Americans, or 55 percent, are considered overweight according to guidelines from the National Institutes of Health. The new standard is based upon a person's body mass index (BMI) -- a way of measuring body weight in relation to height and body fat. This puts them at increased risk for diabetes, heart disease and stroke.

WEIGHT LOSS HELP: A drug currently approved to treat depression and help people quit smoking has shown promise as a potential weight-loss tool. Kishore Gadde, M.D., of Duke University Medical Center realized overweight psychiatric patients in the anti-depression drug were able to lose weight easier and more quickly than those not on the medication. Dr. Gadde began a study to see if the drug could help non-depressed overweight patients lose weight. The average weight of women in the study was 222 pounds. In the first eight weeks of the study, women who took the drug combined with a 1600-calorie a day diet lost four times more weight than women on a placebo. The average daily caloric intake for a woman is about 2100 calories. At the end of the eight week study, those who completed the study and took the drug lost 6.21 percent of their body weight compared with a 1.56 percent weight loss in the women on a placebo.

HOW IT WORKS: Buproprion SR works by increasing available amounts of norepinephrine and dopamine in the brain. The two chemicals are believed to play a role in the reward and pleasure pathways. The drug marketed under the names Wellbutrin SR and Zyban. Dr. Gadde says its unique mechanism of action may account for why patients report buproprion SR does not suppress their appetite. Instead they report feeling satisfied more easily. Buproprion SR is not approved by the FDA for weight loss and is not recommended for use by patients with seizure disorders, anorexia or bulimia. The study will continue for another 18 months. A larger, multi-center trial is planned for the future.

SIDE EFFECTS: The only known side effect from Buproprion SR is dry mouth. Unlike other medications used for depression, it does not affect sexual function. They have not yet tested the drug's long-term effectiveness on weight loss.

OTHER USES: Buproprion is also currently being studied for its effectiveness in relieving nerve pain called neuropathy which can be caused by a number of factors including disease or injury.

FOR MORE INFORMATION, PLEASE CONTACT: Rebecca Levine
Duke University Medical Center
Box 3354
Durham, NC 27710
(919) 684-4148
DATE: 6/6/99

TO: DR. KISHORE GADDE

COMPANY: DUKE UNIVERSITY MEDICAL CENTER

FAX NO.: 919-681-7421

FROM: JOCELYN SERIO

MESSAGE: ATTACHED IS THE ARTICLE FROM THE JUNE 15 LONDON'S DAILY Mail.

Number of Pages including cover page: 2

Reference: 1872

If you do not receive all pages, please call 212-886-2200
Is this anti-depressant a new weight-loss drug?

A DOCTOR has stumbled on a new anti-obesity drug which could become the world's most effective weight-loss treatment. The drug, Bupropion, is designed to treat depression, but when given to clinically obese women they rapidly shed pounds.

Now the British drug company which developed it is considering launching the anti-depressant as a treatment for obesity.

Patients on Bupropion have achieved weight loss equal to and greater than patients on the new anti-obesity drug Xenical, which was launched last year.

Dr Kishore Gadde, a psychiatrist at Duke University Medical Centre in North Carolina, prescribed Bupropion for mild depression while helping women to lose weight at the university's fitness centre.

Dr Gadde found that the women were losing significantly greater amounts of weight than on previous visits to the centre. 'I was amazed, because there had been nothing published about this drug having the ability to help weight loss,' he says.

As a result of his discovery, Dr Gadde persuaded Bupropion's manufacturer, Glaxo Wellcome, to support a trial.

'I wanted to see if the drug would work under proper trial conditions, using a double blind test, because it was possible that what I had observed may have been a fluke.'

The results of a two-month study involving 18 women with an average weight of 15 stone proved the original findings were no mistake. After eight weeks on a diet of 1,600 calories a day, the women had lost up to a stone — 5 pc of their body weight. Women given a placebo lost 1.5 pc of their body weight.

New drug help for slimmers

Dr Gadde says: 'These women, who were significantly overweight, were able to achieve a good weight loss over a short period of time. A lot of them said the drug did not suppress their appetite but helped them feel satisfied more easily. Bupropion acts in a different way to other anti-depressants, working on two brain chemicals, noradrenaline and dopamine, which are both implicated in the reward and pleasure pathways in the brain. This probably explains why patients say the drug helps them feel more satisfied while not suppressing their appetites,' says Dr Gadde.

Although it isn't yet licensed to treat obesity, Dr Gadde expects other doctors will try it out experimentally.

'The important thing is that there are no significant side-effects, apart from a feeling of a dry mouth.'

MARTYN HALLE
NEW DRUG THAT COULD BE BIGGER THAN VIAGRA

By ROGER HENDERSON The Guardian

LONDON - Modern medicine still relies on chance and serendipity far more than it cares to admit. Viagra, the prescription drug phenomenon of the past two years, was originally developed as a treatment for heart disease and it was only when users reported their impotence was a thing of the past that the manufacturers realized they had created a golden goose.

If reports from America are to be believed, a new drug that has properties also discovered by accident may take the United Kingdom by storm next year, and could be set to rival the success of Viagra. If approved, it may also go some way in helping health professionals to achieve their goal of reducing the number of premature deaths in this country from heart disease, as set out in the recent department of health white paper on the health of the nation.

Originally developed as an antidepressant, the drug _ bupropion hydrochloride _ was licensed in the U.S. three years ago under the name Wellbutrin. Its main marketing point was that it did not greatly interfere with sexual function, something most antidepressants are notorious for affecting.

During trials of the drug, and quite by chance, it was realized that people taking Wellbutrin were finding it far easier to stop smoking than those who were not using it. Early reports suggested that they were not craving for cigarettes as they normally did, and had fewer withdrawal symptoms on stopping their habit.

Once the company involved, Glaxo Wellcome, had picked up on this aspect of the drug, it began further trials specifically looking at the effectiveness of the drug as an anti-smoking aid. The results of this comparative clinical study were published in the New England Journal of Medicine in March this year, and make for impressive reading.

Just under 500 smokers were involved, all of whom smoked at least 15 cigarettes a day. They were split into four groups, those taking a dummy pill or placebo, those taking bupropion, those using a nicotine patch plus a bupropion tablet, and those using a nicotine patch alone.

After 12 months, 15 percent of those on the dummy pill were still not smoking. This was only marginally worse than the 16 percent using only nicotine patches, but nearly 31 percent of smokers taking bupropion had stopped. The surprising statistic, however, was in the group using both patches and bupropion — a success rate of 35 percent, more than double the usual rate seen in smokers trying to give up.

Just as important, side effects appeared to be minor, with few people having to stop the drug because of them. A dry mouth and insomnia were reported by users, but little else. People with a history of seizures or eating disorders should not take bupropion, but otherwise most smokers will be valid candidates for such treatment, which is the first such non-nicotine prescription available.

This combination of effective results and low side effects led to the drug being licensed in the U.S. as an aid to stopping smoking, under the name Zyban. This has now been prescribed to some 3 million Americans, over 1 million of whom have stopped smoking.

Attempts are now being made to secure a license across the EU, with the Dutch authorities taking the lead through the regulatory hoops. The drug could be available in this country early next year.

Rob Cohen, therapeutic and science communications manager of Glaxo Wellcome, says: "With success rates double that of nicotine replacement therapy, Zyban, upon approval from the appropriate regulatory authorities, will provide an effective weapon for many people in their battle against
Weilbutrin Makes Them Thin And Happy

A psychiatrist who noticed his depressed patients were losing weight may have stumbled across a new diet drug.

Kishor Gadde, M.D., of Duke University Medical Center, Durham, NC, led a team of researchers who examined the effects of Wellbutrin (bupropion SR, Glaxo Wellcome), an antidepressant, on 31 overweight women. Study participants weighed 222 pounds on average.

After eight weeks of treatment and a 1,600-calorie daily diet, the 18 women on the drug lost more than six percent of their body weight, four times more than 12 women who received a placebo. The treated women received a maximum of 200 mg of bupropion daily.

Gadde reported his results in May at the American Psychiatric Association meeting in Washington, DC.

The study was funded by Glaxo Wellcome. Gadde cautioned that bupropion, which is also marketed as Zyban for smoking cessation, is not approved by the FDA for weight loss. The main side effect noted was dry mouth. —DAN VERGANO
Drug may help folks be happy, lose weight and stop smoking

WASHINGTON — A drug already approved to combat depression and help people stop smoking has shown promise as a weight-loss tool in a small, preliminary study, researchers say.

Speaking during a meeting of the American Psychiatric Association here earlier this week, Dr. Kishore Gadde of Duke University said a small group of women taking inactive pills. All the women were also on a relatively modest 1,500 calorie-a-day diet.

Gadde said tests with the drug — which is sold as Zyprexa as a stop-smoking aid and as Wellbutrin for depression — are continuing, and that the women who responded during the first eight weeks appear to be losing additional weight as they continue taking the drug more than six months out, although the researchers haven't completed analyzing their data.

"While we have to approach the results cautiously because the long-term results are not completed, we are very excited about the potential the drug has for treating obesity."

The psychiatrist first noticed that the drug seemed to have an effect on weight among a group of women he was treating for mild depression at a Duke diet and fitness center.

Previous studies noted that people taking the drug gained less weight as they quit smoking.
Imagine taking a pill and POOF! Your hunger goes away. The pounds melt off. Best of all, you feel great, not anxious like with some appetite suppressants. That's what doctors are finding by using an old pill a new way.

Jan Lucas has dropped five dress sizes in one year. "I weighed 217, and now I weigh 145," Jan says. She did it by eating 1,600 calories a day, just slightly less than average for most women. However, she also took an anti-depressant pill called bupropion SR.

Before long, Jan knew this diet would be different. "Other times when I lost weight, I really wanted to eat more food," she says. "I was never satisfied. Now, I feel like it's the answer to my prayers. I just don't have the cravings."

Kishore Gadde, M.D., a psychiatrist at Duke University Medical Center in Durham, N.C., came up with the idea after he noticed obese patients taking the anti-depressant lost weight more successfully. He studied about 30 women who were overweight but not depressed.

Dr. Gadde reports, "The people who received bupropion SR did four times better than those who received a placebo."

After eight weeks, women taking the drug lost an average of 14 pounds. Those on a placebo lost
only three-and-a-half pounds. The drug triggers the release of dopamine and norepinephrine in the brain. "It's a brain chemical or a brain hormone we normally associate with pleasure feeling," says Dr. Gadde.

He hopes more studies will show why the drug is so helpful to dieters. Jan remains in the study counting calories and loving her new look. "I feel like I can do this for the rest of my life," she says.

So far, the only side effect of the drug seems to be a dry mouth. It could be two years before the drug is cleared for use as a diet aid. Right now, many doctors prescribe it to help smokers kick the habit (Zyban).

If you would like more information, please contact:

Rebecca Levine
Duke University Medical Center
Box 3354
Durham, NC 27710
(919) 684-4148

Or you can share your comments with other readers here.

Click here to order additional research and full length news video.

End obsessive eating with Overeaters Anonymous.
Feel good, quit leaf — & get thin with drug?

By JIM SHAMP
The Herald-Sun

If you're depressed about the idea of gaining weight when you quit smoking, Glaxo Wellcome Inc. may have just the drug for you.

Glaxo's drug bupropion, sold as Wellbutrin SR for treating mild depression and, in a different form as Zyban to help people quit smoking, may have yet another life as a weight-loss agent.

Duke University Medical Center psychiatrist Kishore Gadde unveiled results of a preliminary study Tuesday in Washington, D.C., showing that women taking the drug while maintaining a 1,600-calorie-a-day diet lost four times more weight than women eating the same amount while taking a placebo — a pill that looks the same but contains no medicine.

His presentation to the American Psychiatric Association marks only the latest in a series of findings that could lead to a third new indication for bupropion, an old Burroughs Wellcome drug that has found financial legs since Burroughs was taken over by Glaxo Inc. in 1995.

Doctors initially noticed that depressed smokers trying to kick the habit had impressive results when taking Wellbutrin. Research studies ensued, resulting in the introduction of the drug as Zyban. A study published in the New England Journal of Medicine has since shown that 30 percent of smokers who took Zyban were able to quit and stay tobacco-free — double the percentage who quit with a placebo.

Similarly, physicians have been noticing weight loss seems easier for people using some form of the medication. Now, the Duke study is taking it a step further.

Gadde said he got the idea for his study while consulting at the Duke Diet and Fitness Center. He noticed when he gave patients the drug to treat mild depression, they lost more weight than usual.

So, he approached Glaxo with a proposal to test Wellbutrin SR in a group of 50 non-depressed women weighing an average of 222 pounds. He said he chose the 1,600-calorie diet because it's only 500 calories below an average

With the line of hopeful ticket purchasers behind them, Jon Toffe (above, left) and Jesse Stewart duel with lightsabers Tuesday evening in front of the Wynnsong Theatre in Durham. Both spent the night in front of the theater to get tickets for "Episode 1 — The Phantom Menace." Tickets went on sale at noon for the midnight and 3 a.m. showings Wednesday. Ross Haswell of Durham reads a book while waiting in line for tickets to the new Star Wars movie.
woman's daily intake, so it would be safe and tolerable.

"It was designed to quickly get an answer," he told The Herald-Sun. "We wanted to figure out whether it was worthwhile doing a large study. The results were obviously very positive."

Of the 50 women who started, 21 were assigned to receive the placebo and 29 to get bupropion. Only 31 completed the full eight weeks of the initial trial, in which participants kept diaries logging their food intake. Women receiving the drug were given up to 200 milligrams twice a day, considered the maximum dosage for treating depression.

"In weight-loss studies, if people aren't losing weight, it's hard to keep them in the study," said Gadde. "We asked those who dropped out why they didn't finish. We found 32 percent in the placebo group dropped out because they were dissatisfied with the results, compared with only 4 percent in the bupropion group."

Of the women completing the study, those getting the drug lost an average of 14 pounds, compared with an average loss of only 4.5 pounds in the group receiving placebo.

"Of those receiving the drug, 12 out of 19 — 67 percent — completed the study, compared with only two out of 13, or 15 percent, of those receiving placebo," said Gadde. "Another significant finding. Gadde said, was that bupropion was tolerated "remarkably well, with no significant side effects."

Only one of the women in the study was a smoker, he said. "Now we are going to do more large-scale studies," said Gadde. "At this point it looks very promising. We'll be releasing results of our six-month evaluation phase very soon. All we can say at this point is that the 18 women who are continuing the study seem to be continuing to lose weight. It's such an objective measure we can't really hide it."

Only women who lost 5 percent of their initial body weight, or four kilograms, in the first eight weeks, qualified for continuation in the study, said Gadde. Though they're all continuing to lose weight, he said he doesn't know how many are receiving the drug and how many are on placebo.

"We tried to take away something that benefited them, whether it was placebo or drug," said Gadde. "But if they failed to benefit adequately in the first eight weeks, we offered them the chance to cross over to the other medication in the double-blind trial. If they respond to the cross-over treatment in the second eight weeks, they'll be able to go into the next phase, for up to two years, as responders. But we're blinded to the treatment. Only the pharmacy knows what they're getting."

"The researchers used body composition scans, called DEXA scans, to measure the women's percentage of fat and muscle mass. When you lose weight on a balanced diet you lose approximately three-fourths fat and one-fourth lean mass," said Gadde. "But when you fast, you lose half fat and half lean mass. That's why fasting is not a good way to lose weight, because you lose a lot of lean mass."

The DEXA scans at the beginning of the study will be repeated after six months of treatment, at the end of one year and at the end of two years, to evaluate the quality of weight loss in the participants, said Gadde. The scientists are also looking at bone mass density, because women who lose weight also lose a certain amount of bone mass, increasing their risk of osteoporosis.

Gadde said many participants reported feeling pleasure after eating smaller amounts of food. They didn't say they felt full, just satisfied, said Gadde.

The researcher said the drug's effect is possibly related to brain chemicals, the apparent dopamine-enhancing and norepinephrine-enhancing effects of the drug.

"These neurotransmitters modulate pleasure and reward behaviors in the brain," he said. "But the mechanism is not well understood."

These neurotransmitters are also known to affect energy expenditure, he noted. Energy intake is the food we eat, while its expenditure is how calories are burned. Gadde projected that the drug helps people reduce their desire for intake, while also helping them burn calories more efficiently.

Unlike fenfluramine and dexfenfluramine — Fen-Phen, the diet drug which was withdrawn from the market over safety concerns, bupropion appears to have no effect on the neurotransmitters, serotonin, said Gadde.


Pharmaceutical analyst Edmund Deiber has projected that sales of the three versions could reach $300 million by the end of this year.

Raleigh officials object to immunity for reporters

Associated Press
RALEIGH — Raleigh Mayor Tom Funder and two members of his City Council have been sued in federal court because of the 2,000-foot zoning area the city's ordinance violates the Amendment for two reasons.

First, the government cannot regulate adult entertainment because of the 2,000-foot zoning area. Second, the City Council's zoning decision rezone adult businesses simply because it doesn't like them, he said. We've got to consider the "second effects" of adult businesses and land-use decisions based on the facts.

But Brough, considered an ally on land-use law, said city officials cannot conduct any studies to determine whether adult establishments affect the character of the neighborhood when they included an add-on provision in the 1993 zoning code.
A pill for all that addicts you?

Monday, 17 September 2001 20:43 (ET)

A pill for all that addicts you?
By PEGGY PECK, UPI Science News

CLEVELAND, Sept. 17 (UPI) -- A medication called bupropion, better known as Wellbutrin or Zyban, is generating a lot of buzz because it looks a wonder drug that can help people lose weight or stop smoking. The buzz is especially interesting because the drug initially was approved to treat depression.

So does this mean that depression, overeating, smoking and maybe other addictions like drug abuse or alcoholism are all somehow linked? The answer, say addiction experts, is maybe.

When smokers light up a cigarette and down a lung-full of smoke, nicotine triggers the release of a chemical called dopamine in the brain. Dopamine, in turn, acts on the pleasure center of the brain, which sends out those waves of pleasure that longtime smokers describe.

Likewise, dopamine is released when eat. "You know you've eaten enough when you feel full or sated," Dr. Kishore Gadde of Duke University told United Press International. But obese people often need to eat large amounts of food -- in fact need to over-eat -- to release enough dopamine to feel sated. "They may actually need higher levels of dopamine," he said.

People who are depressed, on the other hand, cannot get that dopamine high from smoking or eating or any other known dopamine triggers. Their dopamine levels remain so low they are incapable of feeling pleasure. That is where bupropion comes into the picture. It also regulates the release of dopamine.

When depressed patients take it, many of them start to feel better. But smokers and overeaters do not have to be depressed to get a benefit from bupropion.

Bupropion is not approved for use in treating other addictions, including alcoholism.

But by taking the drug, the smoker may not feel the need for the nicotine rush and the overeater may be able to push away from the table having consumed fewer calories.

There are several studies indicating the drug is an effective aide for both weight loss and smoking cessation, but addiction specialists are cautious about looking "for a cure in a bottle," said Dr. Howard Rankin.

http://www.vny.com/df/News/updetail.cfm?QID=221956
Rankin, an adjunct professor of psychology at the University of South Carolina School of Public Health in Columbia, told UPI it does appear there is probably a general addiction pathway in the brain, but he questions the wisdom of taking that road.

He said anyone battling an addiction, whether it is overeating or alcoholism, is "very good at looking outside themselves for both the source of the problem and a possible cure." He said that "magic bullet approach" usually is doomed because the affected individual fails to make the needed life changes associated with long-term recovery.

Those changes include a commitment to a "total life change and to ongoing support," Rankin said, and added it can be a 12-step program or professional counseling.

Dr. Tony Tommasello of the University of Maryland at Baltimore, told UPI that drugs like bupropion appear to work best when taken in conjunction with ongoing counseling or support programs. Moreover, a pharmacologic approach to treating addictions is probably most useful in "getting people over the initial difficulties like the physical withdrawal from nicotine."

Tommasello said most long-term recovery is linked to the type of lifestyle changes advocated by Rankin. "In the case of a recovering alcoholic, for example, recovery often turns on the ability of the alcoholic not to resist the urge to drink but to act on that urge in a positive manner, for example by going to an AA meeting," Tommasello said.

But Dr. James Taylor-Hayes, of the Mayo Clinic in Rochester, Minn., said maybe part of the total lifestyle change Rankin and Tommasello advocate should include lifelong medication to treat the addictive disorder. He has been studying efficacy of long-term bupropion treatment lasting a year or more to prevent relapse among former smokers.

Hayes said the bupropion is well tolerated with only a very minimal risk for seizure, and that risk is only seen in people who had a history of head injuries.

Many conditions, for example diabetes or high blood pressure, require chronic treatment with medications. But addictions, according to the experts, are not equivalent to illness like diabetes.

To illustrate, Rankin pointed to the anti-drinking drug called antabuse, which will cause one to become violently ill if taken in combination with alcohol. "I remember a treatment program where we were implanting antabuse under the skin in the arm and I saw people actually digging it out so they could drink. Chemical police just don't work."

---

Copyright 2001 by United Press International.
All rights reserved.

The romantic sounds of classic Cuban music blend with contemporary Spanish guitar in Alicia y Yo, a new CD from Spain. Click here to listen to some tracks and order the CD

Return to headlines.

http://www.vry.com/cf/News/updetail.cfm?QID=221856
COONEY WATERS

Teletypewriter Transmission

Sending Information

DATE: 8-2-99

TO: Dr. Holdre

COMPANY: Duke University

FAX NO.: 919-681-7421

FROM: Lisa Drake

MESSAGE: Attached is a weight loss article from The Sun.

Number of Pages including cover page: 2

Reference: 1850

If you do not receive all pages, please call 212-886-2200
The pill doctors say will help you to slim

...AND THEY DISCOVERED IT BY ACCIDENT

DOCTORS have found a new pill to help you lose weight—purely by accident.

Researchers discovered that a pill used for depression had the unexpected side effect of making patients shed their flab.

There is some evidence it can help people stop smoking.

Dr. Martin Halle, who developed the pill, says:

"By chance we have found that the drug helps people who are depressed to lose weight. The patients were pleasantly surprised because they had not been expecting such an effect. They had been given the drug because they were down about their weight."
Amazing

Bupropion is said to be entirely safe and can be taken for life to prevent weight gain.

The drug has also been discovered to be as effective as the nicotine patch in helping smokers to quit and is due to be launched for that use in Britain later this year.

Though it isn't yet licensed to treat the overweight, Dr. Kitkoff Gaddie, a psychiatrist at Duke University Medical Center, North Carolina, expects doctors around the world to try it experimentally.

Dr. Gaddie prescribed the drug for mild depression while helping women to lose weight at the university fitness center.

"I was amazed by what possible what I had observed may have been a fluke," he said. The results of a two-month study involving 18 women with an average weight of 150 lb proved the original reports were no mistake.

The woman lost up to a stone - six per cent of their body weight - while on a diet of 1,600 calories a day.

Dr. Gaddie is convinced Bupropion will take off as an obesity treatment.

He says: "These overweight women who were able to achieve a good weight loss over a short period of time."

"We still need to carry out further trials with a larger group of patients but it looks as if we have discovered a new drug for this drug."

"The results appear as good as those achieved for Xenical and in some cases even better."

"Some of the women on the trial have been taking the drug for up to a year and are continuing to lose weight."

"Women on the total reported that the drug did not suppress their appetite but helped them feel more satisfied more easily."

"Stimulating drugs have acted by suppressing the desire to eat. This drug acts in a more sophisticated way, by allowing you to eat, but reducing your desire to overeat."

Specialists treating the obese have been short of drug treatments since the banning of popular diet pills phenidrine and fenfluramine after they were blamed for causing heart disease in patients.

Dry

He says: "News of my study is spreading and people are bound to experiment because there are not that many drugs available for obesity."

"The important thing is that there are no significant side effects apart from a feeling of a dry mouth."

But Glass advises GPs not to use it to treat patients suffering from a history of seizures, depression or bulimia.

British doctors will be able to prescribe Bupropion for obesity once it gains a licence for treating smoking.

But it could be some time before it gets official approval as a slimming pill.